These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34890935)

  • 1. Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events.
    Elsherif SB; Anderson M; Chaudhry AA; Kumar SP; Gopireddy DR; Lall C; Bhosale PR
    Eur J Radiol; 2022 Jan; 146():110062. PubMed ID: 34890935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy and the role of imaging.
    Carter BW; Bhosale PR; Yang WT
    Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Imaging in Immunotherapy.
    Ayoub M; Eleneen Y; Colen RR
    Adv Exp Med Biol; 2020; 1244():309-324. PubMed ID: 32301025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Imaging in Immunotherapy.
    Ak M; Eleneen Y; Ayoub M; Colen RR
    Adv Exp Med Biol; 2021; 1342():431-447. PubMed ID: 34972979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
    Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
    Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Imaging in Immunotherapy.
    Eleneen Y; Colen RR
    Adv Exp Med Biol; 2017; 995():141-153. PubMed ID: 28321816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radiological response assessment of modern immunotherapy using iRECIST].
    Persigehl T; Poeppel TD; Sedlaczek O
    Radiologe; 2017 Oct; 57(10):826-833. PubMed ID: 28812098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors: Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST.
    Yirgin IK; Dogan I; Engin G; Vatansever S; Erturk SM
    J Cancer Res Ther; 2024 Jan; 20(1):156-162. PubMed ID: 38554314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring of immunotherapy : Possibilities and limitations].
    Schneider H; Illert AL; Bamberg F; Eisenblätter M
    Radiologe; 2020 Aug; 60(8):711-720. PubMed ID: 32710153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of tumour response to immunotherapy.
    Dromain C; Beigelman C; Pozzessere C; Duran R; Digklia A
    Eur Radiol Exp; 2020 Jan; 4(1):2. PubMed ID: 31900689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iRECIST: how to do it.
    Persigehl T; Lennartz S; Schwartz LH
    Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors.
    Lalchandani UR; Sahai V; Hersberger K; Francis IR; Wasnik AP
    Curr Probl Diagn Radiol; 2019; 48(6):576-585. PubMed ID: 30181058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care.
    Lennartz S; Diederich S; Doehn C; Gebauer B; Grünwald V; Notohamiprodjo M; Sommer W; Schlemmer HP; Persigehl T
    Rofo; 2020 Mar; 192(3):235-245. PubMed ID: 31994155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the
    Sheikhbahaei S; Marcus CV; Sadaghiani MS; Rowe SP; Pomper MG; Solnes LB
    AJR Am J Roentgenol; 2022 Jun; 218(6):940-952. PubMed ID: 34612682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges of evaluating immunotherapy efficacy in solid tumors.
    Bai R; Li W; Du N; Cui J
    Chin J Cancer Res; 2019 Dec; 31(6):853-861. PubMed ID: 31949388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
    Inno A; Lo Russo G; Salgarello M; Corrao G; Casolino R; Galli G; Modena A; Romano L; Pusceddu S; Greco FG; Garassino MC; Gori S
    Tumori; 2018; 104(2):88-95. PubMed ID: 29714647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence.
    Kim N; Lee ES; Won SE; Yang M; Lee AJ; Shin Y; Ko Y; Pyo J; Park HJ; Kim KW
    Korean J Radiol; 2022 Nov; 23(11):1089-1101. PubMed ID: 36098343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radiology in the evaluation of the immunotherapy efficacy.
    Calandri M; Solitro F; Angelino V; Moretti F; Veltri A
    J Thorac Dis; 2018 May; 10(Suppl 13):S1438-S1446. PubMed ID: 29951295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Re-Analysis of Cancer Vaccine Patients with Immune-Related Clinical Response Criteria(irRC)].
    Nishida K; Saito T; Urakawa S; Mori M; Kakimi K; Doki Y; Wada H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1466-1468. PubMed ID: 30382047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Response criteria for malignant melanoma: RECIST and irRC].
    Spiro J; Maintz D; Persigehl T
    Radiologe; 2015 Feb; 55(2):127-35. PubMed ID: 25637198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.